Patients with Hansen's disease are liable to develop non-healing trophic ulcers. The aim of this study was to determine the efficacy of autologous platelet rich fibrin (PRF) applied at weekly intervals in the management of trophic ulcers. The mean age of the patients, duration and size of ulcer were 44.3 years, 7.4 months and 6.25cm2 respectively. After the third sessions of weekly dressing, there was a significant reduction in the ulcer area (p value = 0.015). All ulcers healed by a maximum of six weeks. No adverse events were noted. PRF thus seems a feasible, safe, simple and cost-effective treatment method.
NagarajuUSundarPKAgarwalP,et al.Autologous platelet-rich fibrin matrix in Non-healing trophic ulcers in patients with Hansen's Disease. J Cutan Aesthet Surg.2017; 10: 3–7. PubMed PubMed.
2.
ShreyasNSAgrwalSAgrwalC,et al.Efficacy of autologous platelet-rich fibrin in chronic cutaneous ulcer: a randomized controlled trial. Indian Journal of Clinical and Experimental Dermatology2017; 3: 172–181.
3.
O'ConnellSMImpedugliaTHesslerK,et al.Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen2008; 16: 749–756. PubMed PubMed.
4.
ChoukrounJAddaFSchoefflerC,et al.An opportunity in perioimplantology: the PRF. Implantodontie2001; 42: 55–62. PubMed.
5.
LondahlMTarnowLKarlsmarkT, et al.Use of an autologous leucocyte and platelet-rich fibrin patch on hard-to-heal DFUs: a pilot study. J Wound Care2015; 24: 172–174. PubMed, 6–8.
6.
ShettySShenoiSD. Autologous platelet-rich fibrin in treatment of scleroderma ulcer. Int Wound J2016; 13: 1065–1066. PubMed.
7.
Pinto NR, Ubilla M, Zamora Y, et al. Leucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets 2018; 29: 468–475.
8.
ChiaravallotiAJZubkovBZubkovA. Treatment of a chronic cutaneous surgical wound With platelet-rich fibrin. Dermatol Surg2018; 44: 449–452.
9.
Dohan EhrenfestDMBieleckiT, et al.Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol2012 Jun; 13: 1145–1152.
